S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Alison Durant Joins Mark43 as Chief Marketing Officer

With thirty years of experience scaling SaaS and fintech firms, Alison Durant has been named Chief Marketing Officer at Mark43. Her appointment arrives as the cloud-native public safety platform accelerates its growth trajectory, following the recent acquisition of data intelligence firm ForceMetrics to bolster its market presence.

Alison Durant Joins Mark43 as Chief Marketing Officer
Photo: Bio & News

Durant arrives at a pivotal moment for the New York-based company, which provides records management and computer-aided dispatch systems to more than 300 public safety agencies. CEO Bob Hughes highlighted her track record in aligning marketing organizations with product strategy as a critical asset for the firm’s next phase of expansion. Previously, Durant served as CMO at EngageSmart, where she guided the company through its 2021 initial public offering, and held leadership roles at LogMeIn and Oracle.

At Mark43, her mandate involves sharpening the company's go-to-market strategy and deepening integration between customer insights and commercial execution. Durant noted that the firm’s existing foundation in public safety technology provides a unique opportunity to scale its platform and reach a broader range of state, local, and federal agencies. Her arrival signals a push to unify the company’s outreach as it integrates the capabilities gained through its recent acquisition of ForceMetrics.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!